Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain

Friday, July 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals has reported positive preclinical results for its oral drug candidate MIRA-55, aimed at treating chronic inflammatory pain without opioids. The optimized formulation showed favorable oral bioavailability and effective distribution in the brain and liver. This development supports the potential of MIRA-55 as a non-opioid therapy.
Price reaction · baseline $0.92 (2026-07-09 close) · hit pre-market · clean, no other MIRA news in the window
day 0 close
+0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful formulation results for MIRA-55.
  • Demonstrated favorable oral bioavailability.
  • Robust brain and liver distribution observed.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+5%
120-day peak, hindsight
Typical move
0.6%
average across 2 past catalysts
Cash runway
~21 mo
Low dilution risk

Full Press Release Details

Optimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain and Liver Distribution Following Oral Administration MIAMI, FL / ACCESS Newswire / July 10, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”) , a clinical-stage pharmaceutical company, today announced positive results from preclinical studies evaluating optimized oral formulations of MIRA-55, the Company’s oral drug candidate being developed as a non-opioid therap…
You can read the full content here
The post MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain appeared first on MIRA Pharmaceuticals, Inc. (MIRA) .

Frequently Asked Questions

What is MIRA-55?

MIRA-55 is an oral drug candidate developed by MIRA Pharmaceuticals for chronic inflammatory pain.

What are the results of the preclinical studies?

The preclinical studies showed positive results, indicating favorable oral bioavailability and distribution.

How does MIRA-55 differ from traditional pain therapies?

MIRA-55 is designed as a non-opioid therapy, aiming to provide pain relief without the risks associated with opioids.

What is the significance of oral bioavailability?

Favorable oral bioavailability means that MIRA-55 can be effectively absorbed and utilized by the body when taken orally.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA Pharmaceuticals MIRA-55 chronic pain non-opioid therapy oral formulation
Last updated: Jul 10, 2026

Biotech snapshot

Cash runway
$9M liquidity · $0M/mo burn
~21 mo
Low dilution risk

Catalyst track record

+5%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →